Bioavailability Study of Fexofenadine HCl New Formulation Tablet
NCT ID: NCT06284902
Last Updated: 2025-09-12
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
25 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-02-23
Study Completion Date
2024-05-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of the study is to assess the relative bioavailability of a new galenic form of fexofenadine HCl new formulation tablet (test drug) taken with or without water compared to fexofenadine HCl film-coated tablets (reference form) taken with water under fasting conditions.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrated Tablets 30 mg Under Fasting Condition
NCT01888718
Healthy
COMPLETED
PHASE1
Bioequivalence Study of Dr.Reddy's Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions
NCT01066754
Healthy
COMPLETED
PHASE1
Bioequivalence Study of Dr. Reddy's Laboratories Limited Fexofenadine Hydrochloride 180 mg Tablets Under Fed Conditions
NCT01066767
Healthy
COMPLETED
PHASE1
A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Non-fasting Conditions
NCT00863902
Healthy
COMPLETED
PHASE1
A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food
NCT06624072
Healthy
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Healthy Volunteers
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment Sequence Group 1
Group Type
EXPERIMENTAL
Fexofenadine HCl Coated tablet
Intervention Type
DRUG
Film-coated tablet.
Fexofenadine HCl New Formulation Tablet
Intervention Type
DRUG
New formulation tablet.
Treatment Sequence Group 2
Group Type
EXPERIMENTAL
Fexofenadine HCl Coated tablet
Intervention Type
DRUG
Film-coated tablet.
Fexofenadine HCl New Formulation Tablet
Intervention Type
DRUG
New formulation tablet.
Treatment Sequence Group 3
Group Type
EXPERIMENTAL
Fexofenadine HCl Coated tablet
Intervention Type
DRUG
Film-coated tablet.
Fexofenadine HCl New Formulation Tablet
Intervention Type
DRUG
New formulation tablet.
Treatment Sequence Group 4
Group Type
EXPERIMENTAL
Fexofenadine HCl Coated tablet
Intervention Type
DRUG
Film-coated tablet.
Fexofenadine HCl New Formulation Tablet
Intervention Type
DRUG
New formulation tablet.
Treatment Sequence Group 5
Group Type
EXPERIMENTAL
Fexofenadine HCl Coated tablet
Intervention Type
DRUG
Film-coated tablet.
Fexofenadine HCl New Formulation Tablet
Intervention Type
DRUG
New formulation tablet.
Treatment Sequence Group 6
Group Type
EXPERIMENTAL
Fexofenadine HCl Coated tablet
Intervention Type
DRUG
Film-coated tablet.
Fexofenadine HCl New Formulation Tablet
Intervention Type
DRUG
New formulation tablet.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fexofenadine HCl Coated tablet
Film-coated tablet.
Intervention Type
DRUG
Fexofenadine HCl New Formulation Tablet
New formulation tablet.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male or female non-smokers (no use of tobacco or nicotine products within 3 months prior to screening), ≥18 and ≤55 years of age, with body-mass-index (BMI) \>18 and \<29.9 kilogram per meter square (kg/m\^2) and body weight ≥50.0 kg to ≤100.0 kg for males and ≥40.0 kg to ≤90.0 kg for females.
2. Healthy as defined by:
1. the absence of clinically significant illness and surgery within 4 weeks prior to inclusion on Day 1.
2. the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
3. Standard 12-lead electrocardiogram (ECG) parameters after 5 minutes resting in supine position in the following ranges:120 milliseconds (ms)\<PR\<220 ms, QRS\<120 ms, QTcF≤450 ms if male, ≤470 ms if female and normal ECG tracing unless the Investigator considers an ECG tracing abnormality to be not clinically relevant.
4. Female participants of non-childbearing potential must be:
1. post-menopausal (spontaneous amenorrhea for at least 12 months prior to inclusion on Day 1) with confirmation by documented follicle-stimulating hormone (FSH) levels 30 milli-international units per milliliter (mIU/mL); or
2. surgically sterile (bilateral oophorectomy, bilateral salpingectomy, hysterectomy or tubal ligation) at least 3 months prior to inclusion on Day 1.
5. Female participants of childbearing potential who are sexually active with a non-sterile male partner (sterile male partners are defined as men vasectomized for at least 3 months prior to inclusion on Day 1) must be willing to use one of the following acceptable contraceptive methods throughout the study and for 30 days after the last dose:
1. simultaneous use of hormonal contraceptive (e.g., oral, patch, depot injection, implant, vaginal ring, intrauterine device) or non-hormonal intrauterine device used for at least 4 weeks prior to inclusion on Day 1 (must agree to use the same contraceptive throughout the study) and condom for the male partner;
2. simultaneous use of non-hormonal intrauterine device placed at least 4 weeks prior to inclusion on Day 1 and condom for the male partner;
3. simultaneous use of diaphragm or cervical cap with spermicide and condom for the male partner, started at least 21 days prior to inclusion on Day 1.
6. Male participants who are not vasectomized for at least 3 months prior to inclusion on Day 1 and who are sexually active with a female partner of childbearing potential must be willing to use one of the following acceptable contraceptive methods from the first dose and for 90 days after the last dose:
1. simultaneous use of condom and hormonal contraceptive (e.g., oral, patch, depot injection, implant, vaginal ring, intrauterine device) or non-hormonal intrauterine device used for at least 4 weeks prior to sexual intercourse for the female partner;
2. simultaneous use of condom and a diaphragm or cervical cap with spermicide for the female partner.
7. Male participants (including men who have had a vasectomy) with a pregnant partner must agree to use a condom from the first dose and for 90 days after the last dose.
8. Male participants must be willing not to donate sperm for 90 days after the last dose.
9. Willing to take off dentures or mouth piercing at the time of dosing.
10. Able to understand the study procedures and provide signed informed consent to participate in the study.
2. Healthy as defined by:
1. the absence of clinically significant illness and surgery within 4 weeks prior to inclusion on Day 1.
2. the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
3. Standard 12-lead electrocardiogram (ECG) parameters after 5 minutes resting in supine position in the following ranges:120 milliseconds (ms)\<PR\<220 ms, QRS\<120 ms, QTcF≤450 ms if male, ≤470 ms if female and normal ECG tracing unless the Investigator considers an ECG tracing abnormality to be not clinically relevant.
4. Female participants of non-childbearing potential must be:
1. post-menopausal (spontaneous amenorrhea for at least 12 months prior to inclusion on Day 1) with confirmation by documented follicle-stimulating hormone (FSH) levels 30 milli-international units per milliliter (mIU/mL); or
2. surgically sterile (bilateral oophorectomy, bilateral salpingectomy, hysterectomy or tubal ligation) at least 3 months prior to inclusion on Day 1.
5. Female participants of childbearing potential who are sexually active with a non-sterile male partner (sterile male partners are defined as men vasectomized for at least 3 months prior to inclusion on Day 1) must be willing to use one of the following acceptable contraceptive methods throughout the study and for 30 days after the last dose:
1. simultaneous use of hormonal contraceptive (e.g., oral, patch, depot injection, implant, vaginal ring, intrauterine device) or non-hormonal intrauterine device used for at least 4 weeks prior to inclusion on Day 1 (must agree to use the same contraceptive throughout the study) and condom for the male partner;
2. simultaneous use of non-hormonal intrauterine device placed at least 4 weeks prior to inclusion on Day 1 and condom for the male partner;
3. simultaneous use of diaphragm or cervical cap with spermicide and condom for the male partner, started at least 21 days prior to inclusion on Day 1.
6. Male participants who are not vasectomized for at least 3 months prior to inclusion on Day 1 and who are sexually active with a female partner of childbearing potential must be willing to use one of the following acceptable contraceptive methods from the first dose and for 90 days after the last dose:
1. simultaneous use of condom and hormonal contraceptive (e.g., oral, patch, depot injection, implant, vaginal ring, intrauterine device) or non-hormonal intrauterine device used for at least 4 weeks prior to sexual intercourse for the female partner;
2. simultaneous use of condom and a diaphragm or cervical cap with spermicide for the female partner.
7. Male participants (including men who have had a vasectomy) with a pregnant partner must agree to use a condom from the first dose and for 90 days after the last dose.
8. Male participants must be willing not to donate sperm for 90 days after the last dose.
9. Willing to take off dentures or mouth piercing at the time of dosing.
10. Able to understand the study procedures and provide signed informed consent to participate in the study.
Exclusion Criteria
1. Any clinically significant abnormal finding at physical examination at screening.
2. Clinically significant abnormal laboratory test results or positive serology test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen and antibody at screening.
3. Frequent history of headaches and/or migraine more than twice a month, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).
4. Positive pregnancy test or lactating female participant.
5. Positive urine drug screen, urine cotinine test, or alcohol breath test.
6. Known allergic reactions to fexofenadine HCl or other related drugs, or to any excipient in the formulation.
7. Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician.
8. Clinically significant ECG abnormalities or vital signs abnormalities (systolic blood pressure lower than 95 or over 140 mmHg, diastolic blood pressure lower than 45 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
9. Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease of ≥20 mmHg in systolic blood pressure, decrease of ≥10 mmHg in diastolic blood pressure, and increase of ≥30 bpm in heart rate within 3 minutes when changing from supine to standing position.
10. History of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine \[PCP\], crack, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to screening.
11. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 10 units for women or 15 units for men of alcohol per week (1 unit = 340 mL of beer 5%, 140 mL of wine 12%, or 45 mL of distilled alcohol 40%).
12. Use of medications for the timeframes specified below, with the exception of hormonal contraceptives and medications exempted by the Investigator on a case-by-case basis because they are judged unlikely to affect the pharmacokinetic (PK) profile of the study drug or participant safety (e.g., topical drug products without significant systemic absorption):
1. any biologics (antibody or its derivatives) given within 4 months prior to inclusion on Day 1;
2. depot injection or implant within 3 months prior to inclusion on Day 1;
3. any drug known to induce or inhibit cytochrome P450 (CYP)3A4 metabolism, including St. John's wort, within 30 days prior to inclusion on Day 1;
4. prescription medications within 14 days prior to inclusion on Day 1;
5. any vaccine, including COVID-19 vaccine, within 28 days prior to inclusion on Day 1;
6. over-the-counter (OTC) medications and natural health products (including herbal remedies such as homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 7 days prior to inclusion on Day 1, with the exception of the occasional use of acetaminophen (up to 2 g daily);
7. any drug known to be P-glycoproteins (Pg-p) inhibitors or inducers, Organic anion transporting polypeptides (OATP) inhibitors or inducers or any medication containing ketoconazole (e.g., Nizoral), itraconazole, verapamil, erythromycin, rifampin, and carbamazepine within 14 days prior to inclusion on Day 1 and during the study period.
8. any antacids containing aluminum and magnesium within 14 days prior to inclusion on Day 1 and during the study period.
9. any antihistaminic drug within 14 days prior to inclusion on Day 1.
10. any tricyclic antidepressants within 14 days prior to inclusion on Day 1.
13. Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to inclusion on Day 1, administration of a biological product in the context of a clinical research study within 90 days prior to inclusion on Day 1, or concomitant participation in an investigational study involving no drug or device administration.
14. Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day).
15. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the first inclusion on Day 1.
16. Presence of orthodontic braces or orthodontic retention wires or dentures, or any physical findings in the mouth or tongue that would be likely to interfere with successful completion of the dosing procedure.
17. Presents difficulty with venipuncture and/or poor venous access.
18. Any reason which, in the opinion of the Investigator, would prevent the participant from participating in the study.
2. Clinically significant abnormal laboratory test results or positive serology test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen and antibody at screening.
3. Frequent history of headaches and/or migraine more than twice a month, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).
4. Positive pregnancy test or lactating female participant.
5. Positive urine drug screen, urine cotinine test, or alcohol breath test.
6. Known allergic reactions to fexofenadine HCl or other related drugs, or to any excipient in the formulation.
7. Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician.
8. Clinically significant ECG abnormalities or vital signs abnormalities (systolic blood pressure lower than 95 or over 140 mmHg, diastolic blood pressure lower than 45 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
9. Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease of ≥20 mmHg in systolic blood pressure, decrease of ≥10 mmHg in diastolic blood pressure, and increase of ≥30 bpm in heart rate within 3 minutes when changing from supine to standing position.
10. History of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine \[PCP\], crack, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to screening.
11. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 10 units for women or 15 units for men of alcohol per week (1 unit = 340 mL of beer 5%, 140 mL of wine 12%, or 45 mL of distilled alcohol 40%).
12. Use of medications for the timeframes specified below, with the exception of hormonal contraceptives and medications exempted by the Investigator on a case-by-case basis because they are judged unlikely to affect the pharmacokinetic (PK) profile of the study drug or participant safety (e.g., topical drug products without significant systemic absorption):
1. any biologics (antibody or its derivatives) given within 4 months prior to inclusion on Day 1;
2. depot injection or implant within 3 months prior to inclusion on Day 1;
3. any drug known to induce or inhibit cytochrome P450 (CYP)3A4 metabolism, including St. John's wort, within 30 days prior to inclusion on Day 1;
4. prescription medications within 14 days prior to inclusion on Day 1;
5. any vaccine, including COVID-19 vaccine, within 28 days prior to inclusion on Day 1;
6. over-the-counter (OTC) medications and natural health products (including herbal remedies such as homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 7 days prior to inclusion on Day 1, with the exception of the occasional use of acetaminophen (up to 2 g daily);
7. any drug known to be P-glycoproteins (Pg-p) inhibitors or inducers, Organic anion transporting polypeptides (OATP) inhibitors or inducers or any medication containing ketoconazole (e.g., Nizoral), itraconazole, verapamil, erythromycin, rifampin, and carbamazepine within 14 days prior to inclusion on Day 1 and during the study period.
8. any antacids containing aluminum and magnesium within 14 days prior to inclusion on Day 1 and during the study period.
9. any antihistaminic drug within 14 days prior to inclusion on Day 1.
10. any tricyclic antidepressants within 14 days prior to inclusion on Day 1.
13. Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to inclusion on Day 1, administration of a biological product in the context of a clinical research study within 90 days prior to inclusion on Day 1, or concomitant participation in an investigational study involving no drug or device administration.
14. Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day).
15. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the first inclusion on Day 1.
16. Presence of orthodontic braces or orthodontic retention wires or dentures, or any physical findings in the mouth or tongue that would be likely to interfere with successful completion of the dosing procedure.
17. Presents difficulty with venipuncture and/or poor venous access.
18. Any reason which, in the opinion of the Investigator, would prevent the participant from participating in the study.
Minimum Eligible Age
18 Years
Maximum Eligible Age
55 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Opella Healthcare Group SAS, a Sanofi Company
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Sciences & Operations
Role: STUDY_DIRECTOR
Sanofi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Syneos Health Clinic inc.
Québec, Quebec, Canada
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Canada
Related Links
Access external resources that provide additional context or updates about the study.
https://www.trialsummaries.com/Study/StudyDetails?id=25620&tenant=MT_SNY_9011
BDR17987 Plain Language Results Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BDR17987
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Bioavailability Study of Famotidine Tablets 40 mg Under Fasting Conditions
NCT01511731
COMPLETED
PHASE1
A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting Conditions
NCT00864279
COMPLETED
PHASE1
Bioequivalence Study of Desloratadine and Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions
NCT01373138
COMPLETED
PHASE1
Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fasting Condition
NCT01064102
COMPLETED
PHASE1
Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's and Allegra D 24 Hour ER Tablets Under Fasting Conditions
NCT01133470
COMPLETED
PHASE1
Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fasting Condition
NCT01506050
COMPLETED
PHASE1
A Study Comparing Amounts of Tafamidis In The Blood Without Food
NCT02697864
COMPLETED
PHASE1
A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fasting Condition
NCT01079065
COMPLETED
NA
Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fasting Conditions
NCT00776139
COMPLETED
NA
Bioavailability Study of Torsemide Tablets Under Fasting Conditions
NCT00653549
COMPLETED
PHASE1
Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fed Conditions
NCT00776022
COMPLETED
NA
Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fasting Conditions
NCT01506076
COMPLETED
PHASE1
Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions
NCT01314352
COMPLETED
PHASE1
Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fed Condition
NCT01064115
COMPLETED
PHASE1
Bioavailability Study of Dr. Reddy's Desloratadine Tablets, 5 mg Under Fasting Conditions.
NCT01314339
COMPLETED
PHASE1
Cetirizine Chewable Bioequivalence and Food Effect Study
NCT03772158
COMPLETED
PHASE1
To Demonstrate the Relative Bioavailability Study of Loratadine 10 mg Tablets
NCT00946608
COMPLETED
PHASE1
Bioavailability Study of Torsemide Tablets Under Fed Conditions
NCT00654043
COMPLETED
PHASE1
Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg
NCT00650065
COMPLETED
PHASE1
A Comparative Study of Rupatadine 10 mg Tablets and Clarinex® 5 mg Tablets Under Fasting Conditions
NCT05356143
COMPLETED
PHASE1
Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fed Condition
NCT01506037
COMPLETED
PHASE1
A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fed Condition
NCT01079052
COMPLETED
NA
A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects
NCT03517930
COMPLETED
PHASE1
Fed Bioavailability Study of Zonisamide Capsules
NCT00687167
COMPLETED
PHASE1
Leflunomide 20 mg Tablets Under Fasting Conditions
NCT00834418
COMPLETED
PHASE1